mgt show and tell at 11am today for those interested

CGS not waiting and cutting costs. guidance appears for 2h to be running at similar rates to the disappointing FH. the cost cutting will give CGS extra breathing room until demand reappears. an interesting feature is the benefit run rate nearly $3m and costs of implementation under $1m, 3X is quite high usually they are around 1X. if true good return on spend. CGS in waiting mode by the looks of it.

Came across this on my walk, US micro "guru" Ian Cassel talking about the turmoil in CGS share rpice, he is still a big holder.

interesting starts around 46 minute mark.

as an aside, soem of the US interviewers i find really annoying, nothing on SM!

disc held

https://microcapclub.com/2023/03/the-business-brew-podcast-with-ian-cassel/?utm_source=MicroCapClub&utm_campaign=55e93b5beb-RSS_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_2ffd571424-55e93b5beb-164930521

good to see director buying on this dip. Brad OC plus Myer director +$50k each on market is my reading.

Anyone have any idea why CGS has fallen so quickly. i realise that it also went up a lot. only asx announcement is that AEF are sellers, which if redemptions, could be a buy oppty. may be worth waiting for the dust to settle on this one, unless you are privy to what is going on.

Continuing on from yesterday please find a link below to the story. entertaining if nothing else

https://endpts.com/cms-to-restrict-coverage-of-biogens-controversial-alzheimers-drug-to-only-clinical-trials/

ALERT: CMS to restrict coverage of Biogen's controversial Alzheimer's drug to clinical trials

As reported by Endpoint. CMS manages the Medicare program of reimbursements.

Looks bearish the extent of bearishness is open to debate.

CGS-recently sold in IRL